Dual-Targeting TrxR-EGFR Alkynyl-Au(I) Gefitinib Complex Induces Ferroptosis in Gefitinib-Resistant Lung Cancer via Degradation of GPX4
Journal of Medicinal Chemistry · 13.03.2025 · 68 (5) · 5275-5291
DOI: 10.1021/acs.jmedchem.4c02252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 19.02.2025. Verfasst von Lingling Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, National Health Commission (NHC) Key Laboratory of Respiratory Disease, Tongji Hospital, Tongji…. Hauptthemen laut MEDLINE: Gefitinib, Ferroptosis, Lung Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Gefitinib exhibits significant clinical efficacy in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) sensitive mutations. However, its efficacy is severely limited by acquired resistance. Herein, we designed and synthesized a series of dual-targeting thioredoxin reductase (TrxR)-EGFR gold complexes by attaching a gold ligand to the parent structure of gefitinib, 4-anilinoquinazoline. Among them, L1Au2 exhibited significant activity against both gefitinib-sensitive and resistant lung cancers, effectively inhibiting tumor proliferation and promoting apoptosis. Mechanistically, L1Au2 effectively inhibits TrxR and EGFR both in vitro and in vivo. Additionally, L1Au2 promotes the degradation of GPX4 protein via autophagolysosomal and proteasomal pathways, leading to ferroptosis. Notably, L1Au2 also induces endoplasmic reticulum stress (ERS) and triggers immunogenic cell death (ICD). In conclusion, this study provides an innovative strategy for overcoming gefitinib resistance in lung cancer by utilizing dual-targeting TrxR-EGFR alkynyl-Au(I) gefitinib derivatives, thereby offering a new approach for treating gefitinib-resistant lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, National Health Commission (NHC) Key Laboratory of Respiratory Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan…
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, P.R. China.
- Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan 030032, P.R. China.
- Hubei Branch of National Clinical Research Center for Infectious Diseases, Wuhan Pulmonary Hospital (Wuhan Tuberculosis Prevention and Control Institute), Wuhan 430030, P.R. China.
ORCID-Profile: Yunlong Lu, Wukun Liu
Zitieren
APA
Wang, L., Ma, X., Zhou, L., Luo, M., Lu, Y., Wang, Y., Zheng, P., Liu, H., Liu, X., Liu, W., & Wei, S. (2025). Dual-Targeting TrxR-EGFR Alkynyl-Au(I) Gefitinib Complex Induces Ferroptosis in Gefitinib-Resistant Lung Cancer via Degradation of GPX4. Journal of Medicinal Chemistry, 68(5), 5275-5291. https://doi.org/10.1021/acs.jmedchem.4c02252
Vancouver
Wang L, Ma X, Zhou L, Luo M, Lu Y, Wang Y, et al. Dual-Targeting TrxR-EGFR Alkynyl-Au(I) Gefitinib Complex Induces Ferroptosis in Gefitinib-Resistant Lung Cancer via Degradation of GPX4. Journal of Medicinal Chemistry. 2025;68(5):5275-5291. doi:10.1021/acs.jmedchem.4c02252
BibTeX
@article{Wang2025,
author = {Wang, Lingling and Ma, Xiaoyan and Zhou, Ling and Luo, Miao and Lu, Yunlong and Wang, Yawen and Zheng, Pengdou and Liu, Huiguo and Liu, Xiansheng and Liu, Wukun and Wei, Shuang},
title = {Dual-Targeting TrxR-EGFR Alkynyl-Au(I) Gefitinib Complex Induces Ferroptosis in Gefitinib-Resistant Lung Cancer via Degradation of GPX4},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {5},
pages = {5275--5291},
doi = {10.1021/acs.jmedchem.4c02252}
}
EUVIMED